Novavax (NVAX) COVID-19 Vaccine Demonstrates 90% Overall Efficacy and 100% Protection Against Moderate and Severe Disease in PREVENT-19 Phase 3 Trial
Go back to Novavax (NVAX) COVID-19 Vaccine Demonstrates 90% Overall Efficacy and 100% Protection Against Moderate and Severe Disease in PREVENT-19 Phase 3 Trial| Novavax, Inc. (NASDAQ: NVAX) | Delayed: 3.89 --0 (-0%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $3.89 | 52 Week High | $9.23 | |||
| Open | $3.89 | 52 Week Low | $1.16 | |||
| Day High | $3.99 | P/E | N/A | |||
| Day Low | $3.81 | EPS | $-0.30 | |||
| Volume | 2,861,275 | |||||
